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ABSTRACT
Objective An estimated 4.9 million adults received
antiretroviral therapy (ART) in low and middle income
countries in 2009. A further estimated 700000 adults
received ART in high-income countries. The impact of
providing ART is not often quantiﬁable due to limited
monitoring systems. One measure, life-years gained,
provides a standardised measure that shows the survival
impact of ART on the population while controlling for
variations in underlying survival. Measuring life-years
gained allows a comparison of the impact of ART
between regions.
Methods Using the Spectrum computer package, two
different scenarios were created for 151 countries. One
scenario describes the results of providing adults with
ART as reported by countries between 1995 and 2009,
the second scenario describes a situation in which no
ART was provided to adults living with HIV between
1995 and 2009. The difference in the number of life-
years accrued among adults in the two scenarios is
compared and summarised by geographical region.
Results An estimated 14.4 million life-years have been
gained among adults globally between 1995 and 2009 as
a result of ART. 54 % of these years were gained in
western Europe and North America, where ART has
been available for over 10 years. In recent years the
growth in life-years has occurred more rapidly in sub-
Saharan Africa and Asia.
Discussion The substantial impact of ART described
here provides evidence to argue for continued support of
sustainable ART programmes in low and middle-income
countries. Strengthening ART monitoring systems and
mortality surveillance in low and middle-income countries
will make this evidence more accessible to programme
managers.
Since the start of the HIV epidemic, an estimated
25 million people have died of AIDS-related causes.
However, the annual number of persons dying of
AIDS-related causes has been decreasing since
2005.
1 In high-income countries the provision of
antiretroviral therapy (ART) has reduced the
number of deaths signiﬁcantly.
1a 2 However, at the
population level, few published studies from low
and middle-income countries have documented the
impact of ART.
3
Over the past decade there has been a remarkable
increase in the availability of ART to persons living
with HIV in low and middle-income countries.
4
The number of adults on ART has increased from
approximately 300000 in 2002 to just under 5
million in 2009. The reported retention of individ-
uals within ART programmes suggests that
approximately 80% of patients stay in the
programme for at least 12 months.
5 Much of this
increase is a result of governments utilising funding
available from the Global Fund to Fight AIDS, TB
and Malaria or the US government’s President’s
Emergency Plan for AIDS Relief (PEPFAR).
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Measuring the impact of these global and national
programmes is often difﬁcult to quantify despite
the importance of this evidence for continued
funding. A summary measure of the overall reduc-
tion in mortality as a result of ART programmes is
needed to substantiate the beneﬁts of investing
resources into ART programmes.
Using country-level data we estimate the
survival impact of providing ART to approxi-
mately 6 million adults globally (5.3 million adults
in low and middle-income countries and 700000
adults in high-income countries).
4 We estimate
life-years gained among adults as a result of the
availability of ART by region. The number of life-
years gained captures the duration of life extended
because of treatment and is thus an appropriate
measure of impact for diseases that affect younger
populations.
METHODS
During 2009 and 2010 UNAIDS and partners
collaborated with country teams to estimate HIV
incidence and prevalence and the impact of HIVon
their populations. The estimates were developed
through two software packages: the Estimation
and Projection Package (EPP) and Spectrum.
Country teams used the software to create
country-speciﬁc estimates and projections.
Data required as input into EPP include HIV
prevalence data and for concentrated epidemics the
size estimates of the populations most at risk of
HIV. Data required for input into the Spectrum
model include national HIV incidence data gener-
ated by EPP, the annual number of adults receiving
ART, the annual number of women receiving anti-
retroviral prophylaxis to prevent mother-to-child
transmission and the annual number of children
receiving ART. The annual number of people on
ART as reported by governments includes those
individuals who were receiving ART at the end of
the year. Differences from year to year reﬂect those
who have newly initiated ARTand those who have
died or have been lost to follow-up from the ART
programme.
< An additional annexe is
published online only. To view
this ﬁle please visit the journal
online (http://sti.bmj.com).
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SupplementThe country ﬁles submitted to UNAIDS in 2010 were used for
this analysis as well as to create the estimates released by
UNAIDS in November 2010.
1 For countries that did not submit
ﬁles or were not part of the training process, ﬁles were created
based on the best available information from that country.
Full descriptions of EPP and Spectrum are provided elsewhere
in this supplement.
8 9 Here we provide a brief overview. HIV
incidence curves are generated in EPP based on HIV surveillance
data and national ART coverage data. EPP ﬁts a curve to the
available HIV surveillance data creating a national HIV preva-
lence curve. HIV incidence is then calculated from the HIV
prevalence using the ARTcoverage data to account for the longer
survival of individuals who are on therapy. HIV incidence esti-
mated from EPP is used in Spectrum to derive age and sex-
speciﬁc HIV prevalence, which is applied to the population over
time.
The Spectrum computer package is a discrete, compartmental
model that progresses the population by age group through
different stages.
10 Spectrum version 3.52 was used for this
analysis. The population data come from the UN Population
Division’s UN Population Prospects 2008 Revision and include
populations in 5-year age groups as well as age-speciﬁc fertility
rates and mortality rates for individual countries. Spectrum
calculates the number of deaths caused by AIDS while applying
underlying (non-AIDS) mortality to those who do not die of
AIDS-related causes. The underlying mortality is estimated from
non-AIDS life expectancy and model life tables prepared by the
UN Population Division.
11
The population is initialised in the year 1970 to ensure the full
impact of the HIVepidemic is captured in the model. Individuals
move between four stages in Spectrum: HIV negative, HIV
positive and asymptomatic, HIV positive and in need of
treatment (need of treatment can be varied depending on the
country’s guidelines) and dead. Individuals progress from sero-
conversion to need for ART based on progression curves that
reﬂect an ARTeligibility criteria of 200 CD4 cells/mm
3 (in use by
most countries throughout the period of analysis). Once an
individual is in need of treatment they are initially in need of
ﬁrst-line therapy. If they fail on ﬁrst-line therapy they progress
to being in need of second-line therapy. If they fail on second-
line therapy they progress to death. Individuals who do not
receive therapy progress to death over 1.5 years for men and
2 years for women. Individuals receiving therapy (either ﬁrst or
second line) have a 86% chance of surviving the ﬁrst year and
a 90% chance of surviving subsequent years. Mortality due to
AIDS only occurs to individuals who are in need of treatment or
are receiving treatment. Mortality of those lost to follow-up
from the ART programme is captured in the survival parame-
ters.
12 As a result of limitations with the current software it is
not possible to distinguish different survival times based on the
distribution of CD4 cell levels at the start of ART. Individuals are
subject to the probability of dying of non-AIDS-related causes at
all stages. More detailed descriptions and sources for the
parameters used in Spectrum are available elsewhere.
91 2
One of the features of Spectrum is that it allows the user to
create different scenarios by altering country-speciﬁc programme
coverage. Two scenarios were generated for this analysis. In the
ﬁrst scenario adults are provided ART as reported by countries
between 1995 and 2009, in the second scenario adults receive no
ARTat any point during the time period. The two scenarios are
identical except for the provision of ART. The estimated annual
number of life-years gained is estimated by calculating the
difference in the number of people alive in the same year for the
two scenarios. We cumulate the difference of life-years over time
to estimate the survival impact of ART. Regional and global
values of life-years gained were calculated from country esti-
mates. The countries included in each region are deﬁned based
on UNAIDS regional classiﬁcations, which are collapsed to
simplify the presentation of the results. A total of 151 countries
was included in this analysis (countries with a population of less
than 250000 were excluded). The list of countries can be found
within the supplementary annexe (available online only).
A point estimate of the number of persons alive aged 15 years
and older is calculated for each country, for each year, for both
scenarios. These values will have a certain amount of uncer-
tainty based on the variables used in the model to calculate the
point estimate. Spectrum calculates uncertainty bounds (UB) for
the point estimates by running 1000 Monte Carlo runs using
randomly selected parameter values from within a set range.
The uncertainty calculations are described elsewhere.
13 For this
analysis we have applied the uncertainty bounds based on the
difference in people living with HIV for the two scenarios. The
uncertainty bounds are calculated separately for each region.
Children are not included in this analysis because of the
complexity of adjusting for fewer HIV-positive births as women
on ART live longer but are less likely to transmit HIV to their
children. The beneﬁts of increased ART coverage reduce the
overall life-years gained from ARTas fewer children are infected
with HIV. By restricting this analysis to adults over the age of
15 years we avoid this complexity.
RESULTS
Annual life-years gained
Figure 1 shows the change in the annual number of life-years
gained by region over time. The annual number of life-years
gained as a result of ART programmes increased ninefold
between 2005 and 2009 in sub-Saharan Africa (from 155000 to
1465000 (UB 1 291 000 e 1 602 000)), whereas in eastern Europe
and central Asia the number of annual life-years gained increased
by over 16-fold (from 2000 to 38000 (UB 34 000 e 42 000)). In
other regions the annual number of life-years gained in 2009
were 1114000 (UB 959 000 e 1 282 000) in western Europe and
North America, 301000 (UB 247 000 e 327 000) in Latin
America and the Caribbean, 326000 (UB 280 000 e 368 000) in
Figure 1 Annual number of life-years gained among adults due to
antiretroviral therapy, by region, 2000e2009.
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SupplementAsia Paciﬁc, and 5600 (UB 5,000 e 6,200) in the Middle East and
North Africa.
In 2002 over 80% of annual life-years gained were in western
Europe and North America and only 2% were in sub-Saharan
Africa. In 2009 34% of life-years gained were in western Europe
and North America and 45% of life-years gained were in sub-
Saharan Africa. In 2009 9% of life-years gained were in Latin
America and the Caribbean, 10% were in Asia Paciﬁc, 1% were in
eastern Europe and central Asia, and less than 1% were in the
Middle East and North Africa.
Cumulative life-years gained
A more complete summary of the gains from ARTare described
by estimating the cumulative life-years gained since ART was
available. Between 1995 and 2009 an estimated 14.4 million (UB
13.1 million e 15.6 million) life-years were gained as a result of
the provision of ART. The cumulative number of life-years gained
increased rapidly between 2005 and 2009, reﬂecting the
increasing number of adults on ART globally (low, middle and
high-income countries), which grew from 1.9 million in 2005 to 6
million in 2009 (ﬁgure 2).
Figure 3 shows the cumulative number of life-years gained by
region as of 2009. The increase in the number of life-years gained
has been dramatic in some regions and more gradual in others. In
all regions except western Europe and North America and Latin
America and the Caribbean there was over a 50% increase in life-
years gained in 2009 alone. In Latin America and the Caribbean,
and western Europe and North America there were more life-
years gained early in the epidemic. Figure 3 also shows the rapid
increase in life-years gained over time in sub-Saharan Africa, home
to more than two-thirds of people living with HIV in 2009.
ART programmes in sub-Saharan Africa have saved over 3.7
million life-years (UB 3.4 million e 4.0 million) since they became
available. Whereas in western Europe and North America 7.8
million life-years (UB 6.9 million e 8.9 million) have been saved.
In Latin America and the Caribbean 1.8 million life-years (UB
1.4 e 1.9 million) were gained and in Asia Paciﬁca p p r o x i m a t e l y
one million life-years (UB 847 000 e 1 071 000) were gained.
Eastern Europe and central Asia and the Middle East and North
Africa had smaller gains at 87000 (UB 77 000 e 98 000) and
16000 (UB 14 000 e 17 000), respectively (table 1).
DISCUSSION
Between 1995 and 2009 adult ART programmes resulted in an
estimated 14.4 million life-years gained (UB 13.1 million e 15.6
million). More life-years were gained in high-income countries
(western Europe and North America) compared with the other
regions. This difference could be due to a number of factors
including increased accessibility of ART programmes in high-
income countries and more aggressive eligibility criteria in
high-income countries resulting in longer survival time once
they are on ART
13a and, in countries with mature epidemics,
a larger proportion of the HIV population has progressed to
later stages of infection increasing the potential cumulative
life-years gained.
Between 2003 and 2009 there was a dramatic increase in the
number of life-years gained, especially in eastern Europe and
central Asia and sub-Saharan Africa. This coincides with the
rapid roll out of ART as a result of the WHO’s ‘3b y5 ’;
campaign, which improved access to ART in low and middle-
income countries,
14 as well as increased resources through the
Global Fund to ﬁght HIV/AIDS, TB and Malaria and the USA’s
PEPFAR initiative. Before 2003 most of the life-years gained
occurred in western Europe and North America where ART has
been available for over 10 years.
This analysis provides a measure of the global beneﬁts of ART
programmes. Currently, the globally recommended indicators
related to ART measure the proportion of people who receive
treatment among those in need and the proportion of those who
are still on treatment after 12 months among those who started
treatment.
15 Although these indicators are important for
monitoring programmes, they fail to capture the population-
level survival impact of ART.
Surveillance of adult mortality, either cause speciﬁc or all
cause, would be more appropriate to determine the success of
ART programmes. Direct measures of adult mortality can be
captured through vital registration systems; however, very few
countries have vital registration systems that are reliable or from
which cause-speciﬁc mortality is available.
16 Cohort studies or
demographic surveillance sites have shown decreases in
mortality for small areas but do not measure the national,
population-level effect of ART.
11 71 8Some creative attempts
have been made to measure AIDS mortality through other
sources such as burial societies and sales of cofﬁns; however,
these are not reliable sources of data for most countries.
19 20
Verbal autopsies and sibling survival histories can be added to
household surveys to derive population-based estimates of
AIDS-speciﬁc mortality.
21 22 Ideally, national ART programmes
would strengthen their monitoring and evaluation efforts to
measure and report outcomes of their patients. However, even
with strengthened monitoring systems, capturing information
on deaths among patients in the programme excludes individ-
uals who never made it to the clinic or individuals lost to follow-
up from the ART programme.
Figure 2 Cumulative number of life-
years gained among adults due to
antiretroviral therapy (ART),
1995e2009.
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SupplementWhen direct measures are not available from existing sources,
models can be used to estimate the impact of ART programmes.
23 24
Demographic models, such as Spectrum, make it possible to
capture the change in life expectancy or life-years gaineddboth
measures that describe the advantage of saving young lives.
The data used for this analysis have a number of limitations.
Data sources for HIV prevalence are used to provide the estimate
of national HIV incidence. These data are often incomplete and
imperfect in countries.
25 The data provided by countries on the
number of people on ART are also critical to determining how
many life-years were gained over time. The quality of the ART
data in some countries is poor because reporting systems are not
fully functional.
26 In some instances countries are not able to
separate the number of people who started on ART but who
were lost to follow-up from the programme or died. For the
2009/10 round of HIV estimates the programme data used in
Spectrum on the number of people on ARTwere reconciled with
data available from country reports on commitments to the
United National General Assembly Special Session on AIDS,
Universal Access Report and PEPFAR reports. This reconciliation
exercise in 2010 has provided the best available data since
reporting on national ART programmes from low and middle-
income countries began.
Figure 3 Life-years gained in current
year and in previous years among adults
due to antiretroviral therapy, by region,
1995e2009.
Table 1 Estimated number of adults living with HIV and estimated life-
years gained due to antiretroviral therapy, by region, 1995e2009
Adults
(15+) living
with HIV, 2009
1
Cumulative
life-years gained,
1995e2009
Uncertainty bounds
for cumulative life
years gained
Western Europe,
North America
2330000 7767000 (6 912 000 e 8 867 000)
Sub-Saharan
Africa
20300000 3707000 (3 373 000 e 3 987 000)
Latin America,
Caribbean
1580000 1819000 (1 492 000 e 1 937 000)
Asia Paciﬁc 4800000 962000 (847 000 e 1 071 000)
Eastern Europe,
central Asia
1400000 87000 (77 000 e 98 000)
Middle East,
North Africa
440000 16000 (14 000 e 17 000)
30800000 14 360 000 (13 065 000 e 15 610 000)
ii70 Sex Transm Infect 2010;86(Suppl 2):ii67eii71. doi:10.1136/sti.2010.046060
SupplementThe default parameters used in the Spectrum models are
derived from studies that often only cover a limited number of
countries or regions. These parameters are based on the best
available information at the time and are constantly reviewed
and updated by the UNAIDS Epidemic, Modelling and Projec-
tions Reference Group. However, more validation of the Spec-
trum models is needed against empirical data to improve these
assumptions and subsequent analyses. The number of life-years
gained in this analysis is probably an underestimate as the
counterfactual model does not capture the reduced number of
infections as a result of reduced transmission as more people are
receiving ART. When ART coverage is low this will not have
a large effect but as ART coverage is increased this effect on
transmission is likely to be signiﬁcant.
In conclusion, the large number of life-years gained provides
population-level evidence of the dramatic beneﬁts of ART
programmes. This information should encourage decision-
makers to continue investing in sustainable ART programmes in
all regions. As more countries adopt the WHO recommended
ART eligibility criteria of CD4 cell counts less than 350 cells/
mm
3 the number of life-years gained will grow, especially in low
and middle-income countries.
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occurred between 2005 and 2009.
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